Form 4: Director Katina Dorton Receives Equity Grant at Prelude

Director Katina Dorton was granted 38,000 stock options in Prelude Therapeutics Inc. as part of a standard equity compensation package.

Summary

• Director Katina Dorton received an award of 38,000 stock options on June 9, 2026.
• The options have an exercise price of $3.94 per share.
• The options are set to expire on June 8, 2036.
• Vesting occurs on the earlier of the next annual stockholder meeting or the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational or financial trajectory.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $3.94 exercise price.

Future Outlook

The options vest in one year or at the next annual meeting, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while aligning incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in small-cap biopharmaceutical companies.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of the next annual stockholder meeting or June 9, 2027.

Key Dates

Keywords

Prelude Therapeutics, PRLD, Form 4, Insider Trading, Equity Compensation, Director Stock Options